BioSpace News Archive

Labcorp, a global leader of innovative and comprehensive laboratory services, announced new strategic service offerings within its precision oncology portfolio.

Burning Rock Biotech Limited announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC on May 30, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450.

Trinity Biotech plc a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced the launch of its continuous glucose monitoring microsite.

PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim.

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound care, announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.

Skye Bioscience, Inc. today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference being held in New York City.

Medtronic plc announced that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering of €850,000,000 principal amount of 3.650% senior notes due 2029, €850,000,000 principal amount of 3.875% senior notes due 2036, €600,000,000 principal amount of 4.150% senior notes due 2043, and €700,000,000 principal amount of 4.150% senior notes due 2053.

RedHill Biopharma Ltd. announced the issue of a new Chinese patent notice of allowance for opaganib in combination with immune checkpoint inhibitors as a method of inducing an anti-cancer immune response, providing protection for opaganib’s potential use with a range of approved and in-development immune checkpoint inhibitors across a growing range of indications through 2040.

Innoviva, Inc., a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics, and a portfolio of strategic investments in healthcare assets, announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Monday, June 10, 2024 at 1:20 p.m. Eastern Time.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing’s syndrome at ENDO 2024 in Boston, June 1-4, 2024.